REG-Oculis Reports New Phase 2 ACUITY Biomarker Data Further Supporting Privosegtor’s Neuroprotective Potential in Optic Neuritis
Oculis reported new Phase 2 ACUITY biomarker data showing Privosegtor reduced post-onset increases in plasma NfL and GFAP versus placebo in acute optic neuritis. Lower NfL and GFAP levels provide biological evidence of reduced neuroaxonal injury, complementing previously reported +18-letter low-contrast visual acuity gains and preserved retinal structure at Month 3.
Key figures
- Drug Name
- Privosegtor
- Phase Of Trial
- Phase 2
- Lcvl gain
- +18-letter gains in low-contrast visual acuity at Month 3 vs steroid alone
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.